Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study

Simple item page
dc.catalogadorvzp
dc.contributor.authorMondaca Contreras, Sebastián Patricio
dc.contributor.authorPinto, Mauricio P.
dc.contributor.authorBriones Carvajal, Juan Rodrigo
dc.contributor.authorCaire, Nicole
dc.contributor.authorPeña Prado, José Tomas
dc.contributor.authorKoch Hein, Erica Cristina
dc.contributor.authorMuñiz Muñoz, Maria Sabrina
dc.contributor.authorHerrera, María Elisa
dc.contributor.authorSanchez Rojel, Cesar Giovanni
dc.contributor.authorGalindo Aranibar, Héctor Gonzalo
dc.contributor.authorPizarro Brito, Gonzalo Ignacio
dc.contributor.authorAcevedo Claros, Francisco Nicolas
dc.contributor.authorIbáñez Cáceres, Carolina
dc.contributor.authorBalmaceda Araque, Carlos Felipe
dc.contributor.authorNorero, Enrique
dc.contributor.authorDuran, Doris
dc.contributor.authorGarrido Salvo, Marcelo Adán
dc.contributor.authorNervi Nattero, Bruno
dc.date.accessioned2024-01-17T15:14:50Z
dc.date.available2024-01-17T15:14:50Z
dc.date.issued2023
dc.description.abstractObjectives: Perioperative and adjuvant chemotherapy have demonstrated clinical benefits in localized gastric cancer. Nevertheless, the reports on their effects on patient's health-related quality of life (HRQoL) are scarce. Here, we prospectively assessed quality of life and the incidence of chemotherapy-induced peripheral neuropathy (CIPN) in a cohort of patients treated with adjuvant FOLFOX. Methods: Localized stomach or gastroesophageal junction adenocarcinoma patients who underwent curative resection were recruited at a single center. All patients received adjuvant FOLFOX6, and HRQoL and CIPN were assessed using the European organization for research and treatment of cancer quality life (EORTC) C30 and the EORTC CIPN20 questionnaires, respectively. Clinically significant deterioration of HRQoL was also assessed as a coprimary outcome in a longitudinal analysis. Results: We recruited a total of 63 patients. Median age was 62.5 years, and 75% had stomach tumors. Twenty-four weeks after the start of treatment, the probability of being free from HRQoL deterioration and CIPN was 29% (95% confidence interval [CI] 18%-42%) and 6% (95% CI 2%-17%), respectively. Five-year disease-free survival was 45% (95% CI 24%-64%) and 5-year overall survival was 63% (95% CI 48%-76%). Conclusions: Adjuvant FOLFOX is associated with a high rate of long-term survival in localized gastric cancer; nevertheless, it has detrimental effects on patients’ quality of life.
dc.fechaingreso.objetodigital2024-01-17
dc.fuente.origenScopus
dc.identifier.doi10.1016/j.vhri.2022.12.005
dc.identifier.issn2212-1102
dc.identifier.issn2212-1099
dc.identifier.scopusidSCOPUS_ID:85148745856
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80547
dc.information.autorucEscuela de Medicina; Mondaca Contreras, Sebastian Patricio; 0000-0002-1130-0370; 190152
dc.information.autorucEscuela de Medicina; Briones Carvajal, Juan Rodrigo; 0000-0003-4373-0014; 218631
dc.information.autorucEscuela de Medicina; Peña Prado, José Tomas; S/I; 1147816
dc.information.autorucEscuela de Medicina; Koch Hein, Erica Cristina; 0009-0009-2245-8614; 227651
dc.information.autorucEscuela de Medicina; Muñiz Muñoz Maria Sabrina; S/I; 1023831
dc.information.autorucEscuela de Medicina; Sánchez Rojel, Cesar Giovanni; 0000-0002-2920-108X; 135644
dc.information.autorucEscuela de Medicina; Galindo Aranibar, Héctor Gonzalo; S/I; 18813
dc.information.autorucEscuela de Medicina; Pizarro Brito, Gonzalo Ignacio; 0000-0001-9554-8383; 156271
dc.information.autorucEscuela de Medicina; Acevedo Claros Francisco Nicolas; 0000-0003-3482-7746; 119540
dc.information.autorucEscuela de Medicina; Ibáñez Cáceres, Carolina; S/I ; 146063
dc.information.autorucEscuela de Medicina; Balmaceda Araque Carlos Felipe; 0000-0002-8381-2439; 169851
dc.information.autorucEscuela de Medicina; Garrido Salvo Marcelo Adan; ; 7260
dc.information.autorucEscuela de Medicina; Nervi Nattero Bruno; 0000-0002-3016-7261; 604
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final18
dc.pagina.inicio13
dc.publisherElsevier Inc.
dc.revistaValue in Health Regional Issues
dc.rightsacceso abierto
dc.subjectadjuvant chemotherapy
dc.subjectchemotherapy-induced peripheral neuropathy
dc.subjectgastric cancer
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleImpact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study
dc.typeartículo
dc.volumen35
sipa.codpersvinculados190152
sipa.codpersvinculados218631
sipa.codpersvinculados1147816
sipa.codpersvinculados227651
sipa.codpersvinculados1023831
sipa.codpersvinculados135644
sipa.codpersvinculados18813
sipa.codpersvinculados156271
sipa.codpersvinculados119540
sipa.codpersvinculados146063
sipa.codpersvinculados169851
sipa.codpersvinculados7260
sipa.codpersvinculados604
sipa.trazabilidadSCOPUS;2023-08-23
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy.pdf
Size:
921.15 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas